CN115884783A - Ghrh类似物的低剂量药物组合物及其用途 - Google Patents

Ghrh类似物的低剂量药物组合物及其用途 Download PDF

Info

Publication number
CN115884783A
CN115884783A CN202180047566.8A CN202180047566A CN115884783A CN 115884783 A CN115884783 A CN 115884783A CN 202180047566 A CN202180047566 A CN 202180047566A CN 115884783 A CN115884783 A CN 115884783A
Authority
CN
China
Prior art keywords
ghrh
hexenoyl
trans
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180047566.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·马索莱斯
K·施格尔
D·波特文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of CN115884783A publication Critical patent/CN115884783A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180047566.8A 2020-07-05 2021-06-30 Ghrh类似物的低剂量药物组合物及其用途 Pending CN115884783A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
US63/048,167 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (1)

Publication Number Publication Date
CN115884783A true CN115884783A (zh) 2023-03-31

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047566.8A Pending CN115884783A (zh) 2020-07-05 2021-06-30 Ghrh类似物的低剂量药物组合物及其用途

Country Status (9)

Country Link
US (1) US20230270865A1 (https=)
EP (1) EP4175661A4 (https=)
JP (1) JP2023533498A (https=)
KR (1) KR20230035600A (https=)
CN (1) CN115884783A (https=)
AU (1) AU2021306736A1 (https=)
CA (1) CA3183299A1 (https=)
IL (1) IL298991A (https=)
WO (1) WO2022006657A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084009A (zh) * 2003-05-29 2007-12-05 瑟瑞技术公司 Gh促分泌素及其用途
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US20140249083A1 (en) * 2013-03-01 2014-09-04 Theratechnologies Inc. Formulations of growth hormone releasing factor (grf) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CN113646327A (zh) * 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
KR20140027284A (ko) * 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084009A (zh) * 2003-05-29 2007-12-05 瑟瑞技术公司 Gh促分泌素及其用途
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US20140249083A1 (en) * 2013-03-01 2014-09-04 Theratechnologies Inc. Formulations of growth hormone releasing factor (grf) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CN113646327A (zh) * 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GONZÁLEZ-SALES, M等: "Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects", JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, vol. 42, no. 3, 3 June 2015 (2015-06-03), pages 287 - 299 *
叶勇: "制药工艺学", vol. 2, 31 December 2019, 华南理工大学出版社, pages: 271 *
曹运莉;朱珠;: "治疗HIV感染患者脂肪代谢障碍引起的腹部脂肪过多的新药――替莫瑞林", 中国药学杂志, no. 19, 8 October 2011 (2011-10-08), pages 1535 *
邹栩等: "世界上市新药动态与分析", vol. 1, 30 June 2016, 中国医药科技出版社, pages: 177 - 179 *

Also Published As

Publication number Publication date
WO2022006657A1 (en) 2022-01-13
KR20230035600A (ko) 2023-03-14
JP2023533498A (ja) 2023-08-03
IL298991A (en) 2023-02-01
AU2021306736A1 (en) 2023-01-19
EP4175661A4 (en) 2024-08-07
CA3183299A1 (en) 2022-01-13
US20230270865A1 (en) 2023-08-31
EP4175661A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
EP3412310B1 (en) Pharmaceutical formulations of tnf-alpha antibodies
EP2059260B1 (en) Pharmaceutical compositions comprising hGH for oral delivery
TW201605466A (zh) 具有經改善之安定性的藥學組成物（二）
JP2002524514A (ja) タンパク質製剤
EP1631305B1 (en) Sincalide formulations
CN103347532A (zh) 口服可生物利用肽药物组合物及其方法
EP2961432B1 (en) Formulations of growth hormone releasing factor (grf) molecules with improved stability
US20220378880A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
KR20240176455A (ko) 시클로덱스트린을 포함하는 약학적 제형
BG64668B1 (bg) Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда
KR20250051760A (ko) Actrii 항체 고정 단위 용량 치료
CN115884783A (zh) Ghrh类似物的低剂量药物组合物及其用途
CA3037757A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
CN109044980B (zh) 生长抑素冻干粉针剂药物组合物及其制备方法
JP2002516874A (ja) 組換えヒトインターフェロンβ−１Ａ（ＩＦＮ−β−１Ａ）処方物
JP7826337B2 (ja) シクロデキストリンを含む医薬製剤
US20200197494A1 (en) Peptide compositions and methods of use
US20250325560A1 (en) Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
WO1998041222A1 (en) Obesity protein formulations
WO2021129779A1 (zh) 一种新型两亲性蛋白、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination